Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma

Cancer Biology and Therapy

Volumn 13, Issue 14, 2012, Pages 1436-1442

  Botana Rial, Maribel ^a   De Chiara, Loretta ^b   Valverde, Diana ^b   Leiro Fernández, Virginia ^a   Represas Represas, Cristina ^a   Del Campo Pérez, Víctor ^a   Fernández Villar, Alberto ^a  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

Author keywords

Comorbidity; DNA hypermethylation; Lung adenocarcinoma; Malignant pleural effusion; Prognosis; Survival; Treatment

Indexed keywords

BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RETINOIC ACID RECEPTOR BETA;

ADULT; ARTICLE; CLINICAL ARTICLE; DNA METHYLATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; MALE; MALIGNANT PLEURAL EFFUSION; PLEURA EFFUSION; PLEURA FLUID; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENES, P16; GENES, TUMOR SUPPRESSOR; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, RETINOIC ACID; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84870691519     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22004     Document Type: Article

References (27)

1. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. ERS/ATS Statement: Management of malignant pleural effusion. Eur Respir J 2001; 18:402-19; PMID:11529302; http://dx.doi.org/10.1183/09031936.01.00225601.
2. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008; 83:235-50; PMID:18241636.
3. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65(Suppl 2):ii32-40; PMID:20696691; http://dx.doi.org/10.1136/thx.2010.136994.
4. Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF Jr., et al.; International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2:686-93; PMID:17762334; http://dx.doi.org/10.1097/JTO.0b013e31811f4703.
5. Bielsa S, Salud A, Martínez M, Esquerda A, Martín A, Rodríguez-Panadero F, et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med 2008; 19:334-9; PMID:18549935; http://dx.doi.org/10.1016/j.ejim.2007.09.014.
6. Heffner JE, Heffner JN, Brown LK. Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions. Chest 2003; 123:1887-94; PMID:12796164; http://dx.doi.org/10.1378/chest.123.6.1887.
7. Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med 2010; 21:30-4; PMID:20122610; http://dx.doi.org/10.1016/j.ejim.2009.09.012.
8. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117:73-8; PMID:10631202; http://dx.doi.org/10. 1378/chest.117.1.73.
9. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59; PMID:18337604; http://dx.doi.org/10.1056/NEJMra072067.
10. Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet 2012; 81:303-11; PMID:22082348; http://dx.doi.org/10.1111/j.1399-0004.2011.01809.x.
11. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011; 303:21-8; PMID:21255913; http://dx.doi.org/10.1016/j.canlet.2010.12. 011.
12. Ibáñez de Cáceres I, Cairns P. Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction. Clin Transl Oncol 2007; 9:429-37; PMID:17652056; http://dx.doi.org/10.1007/s12094-007-0081-9.
13. Benlloch S, Galbis-Caravajal JM, Martín C, Sanchez-Paya J, Rodríguez-Paniagua JM, Romero S, et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 2006; 107:1859-65; PMID:16983705; http://dx.doi.org/10.1002/ cncr.22190.
14. Brock MV, Hooker CM, Yung R, Guo M, Han Y, Ames SE, et al. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis? Ann Thorac Surg 2005; 80:1241-7; PMID:16181847; http://dx.doi.org/10. 1016/j.athoracsur.2005.05.088.
15. Chen ML, Chang JH, Yeh KT, Chang YS, Chang JG. Epigenetic changes in tumor suppressor genes, P15, P16, APC-3 and E-cadherin in body fluid. Kaohsiung J Med Sci 2007; 23:498-503; PMID:18055295; http://dx.doi.org/10.1016/S1607- 551X(08)70007-X.
16. Katayama H, Hiraki A, Aoe K, Fujiwara K, Matsuo K, Maeda T, et al. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer 2007; 120:2191-5; PMID:17285579; http://dx.doi.org/10.1002/ijc.22576.
17. Katayama H, Hiraki A, Fujiwara K, Matsuo K, Maeda T, Chikamori K, et al. Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer. Asian Pac J Cancer Prev 2007; 8:221-4; PMID:17696735.
18. Karnofsky DA, Abelman WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948; 1:634-56; http://dx.doi. org/10.1002/1097-0142(194811)1:4〈634:: AIDCNCR2820010410〉3.0.CO;2-L.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83; PMID:3558716; http://dx.doi.org/10.1016/0021- 9681(87)90171-8.
20. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 2006; 12:7329-38; PMID:17189404; http://dx.doi.org/10.1158/1078-0432.CCR-06-0894.
21. Kim YT, Lee SH, Sung SW, Kim JH. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann Thorac Surg 2005; 79:1180-8, discussion 1180-8; PMID:15797047; http://dx.doi.org/10.1016/j.athoracsur.2004.09.060.
22. Kim YT, Park SJ, Lee SH, Kang HJ, Hahn S, Kang CH, et al. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2005; 130:1378-84; PMID:16256792; http://dx.doi.org/10.1016/j.jtcvs.2005.06.015.
23. Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 2005; 11:4400-5; PMID:15958624; http://dx.doi.org/10.1158/1078-0432.CCR-04-2378.
24. Hayashi H, Yazawa T, Okudela K, Nagai J, Ito T, Kanisawa M, et al. Inactivation of O6-methylguanine- DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res 2002; 93:184-9; PMID:11856482; http://dx.doi.org/10. 1111/j.1349-7006.2002.tb01257.x.
25. Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004; 202:215-23; PMID:14743504; http://dx.doi.org/10.1002/path. 1507.
26. Bell CG, Beck S. The epigenomic interface between genome and environment in common complex diseases. Brief Funct Genomics 2010; 9:477-85; PMID:21062751; http://dx.doi.org/10.1093/bfgp/elq026.
27. Herceg Z, Vaissière T. Epigenetic mechanisms and cancer: an interface between the environment and the genome. Epigenetics 2011; 6:804-19; PMID:21758002; http://dx.doi.org/10.4161/epi.6.7.16262.